Corrigendum to "Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer" [Eur J Cancer 53 (2016) 51-64]

Affiliations

• ¹ Division of Gynecological Oncology, Leuven Cancer Institute, Department of Gynaecology and Obstetrics, KU Leuven, Herestraat 49, 3000 Leuven, Belgium.
• ² Laboratory for Translational Genetics, Vesalius Research Center, VIB, Leuven, Herestraat 49, 3000 Leuven, Belgium; Laboratory for Translational Genetics, Department of Oncology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium.
• ³ Department of Gynecology and Obstetrics, European Competence Center for Ovarian Cancer, Charité- University Medicine of Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
• ⁴ Division of Gynecological Oncology, Leuven Cancer Institute, Department of Gynaecology and Obstetrics, KU Leuven, Herestraat 49, 3000 Leuven, Belgium; Laboratory for Translational Genetics, Vesalius Research Center, VIB, Leuven, Herestraat 49, 3000 Leuven, Belgium; Laboratory for Translational Genetics, Department of Oncology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium.
• ⁵ Erasmus MC, Cancer Institute, Department Medical Oncology, s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands.
• ⁶ Department of Obstetrics and Gynecology, Molecular Oncology Group, Comprehensive Cancer Center, Gynecologic Cancer Unit, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
• ⁷ Department of Obstetrics and Gynecology, Translational Gynecology Group, Comprehensive Cancer Center, Gynecologic Cancer Unit, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
• ⁸ Laboratory for Translational Genetics, Vesalius Research Center, VIB, Leuven, Herestraat 49, 3000 Leuven, Belgium; Laboratory for Translational Genetics, Department of Oncology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium. Electronic address: Diether.Lambrechts@vib-kuleuven.be.